Market Intelligence, Clinical Progress, and High-Purity Reagents for Adenosine Pathway Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD73/NT5E drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD73 (NT5E) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Active dimeric conformation. |
View CD73 Products |
| Gene Delivery | CD73 (NT5E) Premade Lentivirus Full-length ORF for stable cell line construction. Preserves GPI-anchor expression for native membrane topology. |
View CD73 Products |
| Benchmark Ab | Anti-CD73 (Oleclumab Biosimilar) Recombinant positive control. Sequence Verified. |
View CD73 Products |
| Validator | CD73 (NT5E) siRNA Set For knockdown verification and specificity controls. |
View CD73 Products |
| Related Target: CD39 | ENTPD1 (CD39) Upstream ectonucleotidase in adenosine pathway. Synergistic dual-blockade strategy. |
View ENTPD1 Products |
| Related Target: A2A Receptor | ADORA2A (A2A Receptor) Downstream adenosine receptor. Combination target for pathway complete blockade. |
View ADORA2A Products |
| Related Target: PD-L1 | CD274 (PD-L1) Checkpoint axis frequently co-targeted with CD73 in tumor microenvironment combination strategies. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval (Preclinical translation) | Human/Cyno/Mouse ortholog proteins available with >95% purity; Sequence Verified for binding site conservation. |
| Enzymatic activity preservation (Functional inhibition assays) | ECD-Fc expressed in HEK293 ensuring native glycosylation and proper dimeric conformation for AMP hydrolysis activity. |
| Surface expression validation (GPI-anchor dependent) | Lentivirus particles for stable integration; Preserves native membrane orientation for internalization assays. |
| Epitope specificity (Active site vs allosteric) | Benchmark antibodies (Oleclumab sequence) representing distinct epitope classes available for comparative mapping. |
| False Positives in binding assays | Validated siRNA included for target-specificity verification. |
Live CD73 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD73-targeted therapeutics is intensifying, with major players shifting focus from monotherapy to strategic combinations with PD-1/PD-L1 blockers and A2A receptor antagonists. As first-generation monoclonal antibodies (notably Oleclumab) advance through Phase II/III trials, the next wave of R&D is targeting bispecific constructs (CD73 x PD-1, CD73 x CD39) and ADC formats for enhanced tumor penetration in adenosine-rich microenvironments. The industry consensus is moving toward complete adenosine pathway blockade (CD73 + CD39 + A2AR triple inhibition) to overcome limited monotherapy response rates (<15%).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | AstraZeneca, Bristol Myers Squibb, Novartis | NSCLC, Pancreatic Cancer, TNBC | Enzymatic Inhibition Assay (Need high-purity active ECD-Fc with preserved catalytic sites) |
| Bispecific | Surface Oncology (GSK), Akeso Bio | Solid Tumors (Immuno-oncology) | Heterodimer Validation & Cross-reactivity Panel (Need species-matched antigens for bridging assays) |
| ADC | Emerging Preclinical Programs | Adenosine-high Tumors | Internalization Assay (Need lentivirus-generated stable cell lines with native GPI-anchored expression) |
| Combination Therapy | AstraZeneca + Durvalumab | Immunotherapy-resistant Cancers | Pathway Blockade Assay (Need CD39 + A2AR reagents for complete adenosine axis analysis) |
Molecular Differentiation & Assay Strategy
1. Epitope Differentiation: Active Site Blockade vs. Allosteric/Internalization Induction
- Need: Next-generation antibodies must clearly define mechanism—complete enzymatic inhibition (blocking AMP→Adenosine) for high-adenosine tumors, or internalization-clearing for high-surface-expression tumors.
- Assay Strategy: Use TarMart's CD73 ECD-Fc protein (sequence-verified dimeric conformation) for HPLC/LC-MS-based AMP conversion IC50 assays; use CD73-Lentivirus stable cell lines for pH-sensitive dye internalization flow cytometry.
2. Cross-Species Reactivity: Cyno Model Necessity
- Need: Human and cyno CD73 share ~92% homology, but mouse CD73 (~73%) shows poor cross-reactivity. Preclinical toxicology requires cyno models.
- Assay Strategy: TarMart provides Human/Cyno/Mouse ortholog proteins (>95% purity, <1 EU/µg endotoxin) for SPR/BLI cross-binding kinetics, selecting cyno-positive/mouse-negative candidates to avoid species-related misinterpretation.
3. Glycosylation & Conformational Integrity
- Need: CD73 is a GPI-anchored glycoprotein with N-glycosylation sites (N311, N332); correct glycosylation is critical for enzymatic activity and antibody binding. E. coli expression is unsuitable.
- Assay Strategy: TarMart uses HEK293 expression system for humanized glycosylation. Products include theoretical MW and sequence verification reports; SDS-PAGE confirms glycosylation-induced apparent MW shift (>70 kDa, deglycosylated ~60 kDa).
4. Subfamily Off-Target Screening (Ecto-5'-nucleotidase Family)
- Need: Intracellular isozymes NT5C and NT5C2 may cross-react with CD73 antibodies, causing off-target toxicity.
- Assay Strategy: Provide NT5C/NT5C2 recombinant proteins (customizable) for specificity ELISA or Western Blot cross-reactivity testing, ensuring strict recognition of extracellular CD73 GPI-anchored or unique ECD epitopes.
Related Target Recommendations
Based on adenosine pathway synergistic blockade strategy, cross-sell the following target reagents:
- CD39 (ENTPD1): Upstream ectonucleotidase converting ATP/ADP to AMP (CD73 substrate). Dual blockade completely inhibits adenosine generation. Provide ENTPD1 recombinant protein and inhibitor screening services. (Link: View ENTPD1 Products)
- A2A Receptor (ADORA2A): Downstream adenosine receptor; combination with CD73 inhibitors creates "pathway dual-end blockade" effect. Provide ADORA2A membrane preparations or overexpression lentivirus for cellular functional assays. (Link: View ADORA2A Products)
- CD38 (Optional): Co-expressed with CD73 in immunosuppressive microenvironments, especially in multiple myeloma and AML. Provide CD38 antigen as control for CD73/CD38 bispecific antibody development. (Link: View CD38 Products)